Epcoritamab combination shows strong responses in R/R DLBCL
Last Updated: Tuesday, September 16, 2025
According to new data from the EPCORE NHL-2 trial, epcoritamab plus R-ICE achieved an 87% overall response rate (ORR) and a 65% complete response (CR) rate in patients with relapsed/refractory DLBCL, many of whom proceeded to autologous stem cell transplantation. The regimen demonstrated durable outcomes—at 6 months, 81% of complete responses were ongoing, 74% of patients remained progression-free, and all were alive—while maintaining a manageable safety profile.
Advertisement
News & Literature Highlights
